Copyright
©The Author(s) 2021.
World J Hepatol. Sep 27, 2021; 13(9): 1003-1018
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1003
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1003
Tumor location | Surgery | Liver transplantation | Systemic therapy | Radiation therapy | ||
NeoAdjuvant | Adjuvant | Palliative | ||||
Intrahepatic | Liver resection is first line management, anatomic resection is preferred | Clinical trials and select centers only | Not indicated | Capecitabine | Gemcitabine/Cisplatin; FOLFOX or evaluate for targetable mutations | External beam radiation reduces recurrence in R1 resection |
Perihilar | Liver resection is first line management | Consider if not resection candidate, PSC | Only prior to liver transplant | Capecitabine | Gemcitabine/Cisplatin; FOLFOX | External beam radiation required pre liver transplant |
Distal | Pancreaticoduodenectomy is first line management | Not indicated | Not indicated | Capecitabine | Gemcitabine/Cisplatin; FOLFOX | No defined role |
- Citation: Zori AG, Yang D, Draganov PV, Cabrera R. Advances in the management of cholangiocarcinoma. World J Hepatol 2021; 13(9): 1003-1018
- URL: https://www.wjgnet.com/1948-5182/full/v13/i9/1003.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i9.1003